Remedium Lifecare Past Earnings Performance
Past criteria checks 3/6
Remedium Lifecare has been growing earnings at an average annual rate of 73.9%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 75.5% per year. Remedium Lifecare's return on equity is 52.5%, and it has net margins of 0.7%.
Key information
73.9%
Earnings growth rate
61.4%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 75.5% |
Return on equity | 52.5% |
Net Margin | 0.7% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Remedium Lifecare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 33,454 | 241 | 21 | 0 |
30 Jun 24 | 37,889 | 291 | 21 | 0 |
31 Mar 24 | 40,417 | 327 | 21 | 0 |
31 Dec 23 | 27,254 | 528 | 16 | 0 |
30 Sep 23 | 10,536 | 85 | 18 | 0 |
30 Jun 23 | 7,410 | 42 | 18 | 0 |
31 Mar 23 | 5,098 | 54 | 16 | 0 |
31 Dec 22 | 4,761 | 90 | 14 | 0 |
30 Sep 22 | 5,057 | 82 | 12 | 0 |
30 Jun 22 | 4,660 | 71 | 6 | 0 |
31 Mar 22 | 5,048 | 11 | 11 | 0 |
31 Dec 21 | 5,204 | 25 | 9 | 0 |
30 Sep 21 | 3,278 | 20 | 7 | 0 |
30 Jun 21 | 2,279 | 9 | 2 | 0 |
31 Mar 21 | 900 | 5 | 6 | 0 |
31 Dec 20 | 349 | 5 | 6 | 0 |
30 Sep 20 | 221 | 3 | 2 | 0 |
30 Jun 20 | 29 | 3 | 2 | 0 |
31 Mar 20 | 29 | 3 | 5 | 0 |
31 Dec 19 | 23 | 0 | 1 | 0 |
30 Jun 19 | 3 | 0 | 0 | 0 |
31 Mar 19 | 2 | 0 | 0 | 0 |
31 Dec 18 | 2 | 0 | 1 | 0 |
30 Jun 18 | 3 | 1 | 2 | 0 |
31 Mar 18 | 4 | 0 | 1 | 0 |
31 Dec 17 | 9 | 0 | 1 | 0 |
30 Sep 17 | 9 | 0 | 1 | 0 |
30 Jun 17 | 11 | 0 | 1 | 0 |
31 Mar 17 | 13 | 0 | 1 | 0 |
31 Dec 16 | 27 | 0 | 2 | 0 |
30 Sep 16 | 39 | 0 | 2 | 0 |
30 Jun 16 | 40 | 0 | 1 | 0 |
31 Mar 16 | 39 | 0 | 1 | 0 |
31 Dec 15 | 22 | 0 | 1 | 0 |
30 Sep 15 | 12 | 0 | 1 | 0 |
30 Jun 15 | 16 | 3 | 1 | 0 |
31 Mar 15 | 21 | 6 | 1 | 0 |
31 Mar 14 | 26 | 0 | 1 | 0 |
Quality Earnings: 539561 has a high level of non-cash earnings.
Growing Profit Margin: 539561's current net profit margins (0.7%) are lower than last year (0.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 539561 has become profitable over the past 5 years, growing earnings by 73.9% per year.
Accelerating Growth: 539561's earnings growth over the past year (183.1%) exceeds its 5-year average (73.9% per year).
Earnings vs Industry: 539561 earnings growth over the past year (183.1%) exceeded the Pharmaceuticals industry 20%.
Return on Equity
High ROE: Whilst 539561's Return on Equity (52.52%) is outstanding, this metric is skewed due to their high level of debt.